Cargando…
A Low-Therapeutic Dose of Lithium Inhibits GSK3 and Enhances Myoblast Fusion in C2C12 Cells
Glycogen synthase kinase 3 (GSK3) slows myogenic differentiation and myoblast fusion partly by inhibiting the Wnt/β-catenin signaling pathway. Lithium, a common medication for bipolar disorder, inhibits GSK3 via Mg(+) competition and increased Ser21 (GSK3α) or Ser9 (GSK3β) phosphorylation, leading t...
Autores principales: | Kurgan, Nigel, Whitley, Kennedy C., Maddalena, Lucas A., Moradi, Fereshteh, Stoikos, Joshua, Hamstra, Sophie I., Rubie, Elizabeth A., Kumar, Megha, Roy, Brian D., Woodgett, James R., Stuart, Jeffrey A., Fajardo, Val A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912290/ https://www.ncbi.nlm.nih.gov/pubmed/31671858 http://dx.doi.org/10.3390/cells8111340 |
Ejemplares similares
-
GSK3 inhibition with low dose lithium supplementation augments murine muscle fatigue resistance and specific force production
por: Whitley, Kennedy C., et al.
Publicado: (2020) -
c-Myb Inhibits Myoblast Fusion
por: Kaspar, Petr, et al.
Publicado: (2013) -
Characterization of sclerostin’s response within white adipose tissue to an obesogenic diet at rest and in response to acute exercise in male mice
por: Kurgan, Nigel, et al.
Publicado: (2023) -
Toward countering muscle and bone loss with spaceflight: GSK3 as a potential target
por: Baranowski, Ryan W., et al.
Publicado: (2023) -
Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3β
por: Pansters, N. A. M., et al.
Publicado: (2010)